Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up

Commentary
Video

The associate professor of medicine at University of Colorado discussed updated follow-up data from the phase 3 TRANSFORM trial presented at the 2024 ASCO meeting.

“The FDA approved liso-cel as a second line option for patients with primary refractory and early relapsed large B cell lymphoma if they're transplant eligible based on the TRANSFORM study. So, I think this 3-year update is important to figure out if all of these analyses hold true. The short answer is yes, they do”

Lisocabtagene maraleucel (liso-cel) has continued to demonstrate superiority over standard of care in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) with deep responses.1 The therapy was approved under the name Breyanzi for patients with LBCL whose disease was r/r to first-line treatment within 12 months and patients with LBCL whose disease was r/r to first-line treatment who are not eligible for hematopoietic stem cell transplant based off of the primary analysis of the phase 3 TRANSFORM trial (NCT03575351) in 2022.

Updated, 3-year data from TRANSFORM were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois, by Manali Kamdar, MD, associate professor of medicine – hematology, University of Colorado School of Medicine - Anschutz Medical Campus, and UCHealth Blood Disorders and Cell Therapies Center. CGTLive® spoke with Kamdar to learn more about the new data and how it continues to support the use of liso-cel for second-line LBCL treatment.

Click here to view more coverage from the 2024 ASCO meeting.

REFERENCES
1. Kamdar MK, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7013 
2. US FDA approves Bristol Myers Squibb’s CAR T Cell therapy Breyanzi® for relapsed or refractory large B-cell lymphoma after one prior therapy. News release. Bristol Myers Squibb. June 24, 2022. Accessed June 3, 2024. https://news.bms.com/news/details/2022/US-FDA-Approves-Bristol-Myers-Squibbs-CAR-T-Cell-Therapy-Breyanzifor-Relapsed-or-Refractory-Large-B-cell-Lymphoma-After-One-Prior-Therapy/default.aspx
Related Videos
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Marcus Conant, MD, on More Research Needed With HIV Therapies
© 2024 MJH Life Sciences

All rights reserved.